

AlphaLISA® SureFire® Ultra™

Human p-CHK2 (Thr68) Detection Kit

Product number: ALSU-PCHK2-A500, ALSU-PCHK2-A10K,
 ALSU-PCHK2-A50K, ALSU-PCHK2-A-HV



Kit specificity:


This assay kit contains antibodies which recognize the phospho-Thr68 epitope and a distal epitope on CHK2. The protein detected by this kit corresponds to UniProt ID O96017. CHK2 is also known as Checkpoint kinase-2 and CHEK2. These antibodies recognize CHK2 of human origin. Other species should be tested on a case-by-case basis.

Control lysate information:

Positive Control Lysate: Prepared from HEK293 cells, cultured to confluence in T175 flasks in 10% FBS containing medium, treated with 5 μ M Doxorubicin for 30 minutes and lysed with 4 mL of Lysis Buffer.

Representative data

Data obtained with a 2-plate, 2-incubation protocol. HEK293 cells were seeded at 20K cells/well in a 96 well plate and incubated for 48 hours. Cells were treated with Doxorubicin at the indicated concentrations for 90 minutes. Cells were lysed with Lysis Buffer and assayed separately for Phospho (Thr68) and Total CHK2 using respective SureFire Ultra kits. Equivalent to approximately 4,000 cells/datapoint.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF"